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In this paper we investigate how data openness can be made possi-
ble in communal settings. We adopt a utility perspective that fore-
grounds the use value of data, conceptualizing them as “goods.”
On the basis of this conceptualization we explore 2 key goods' attri-
butes: subtractability and exclusion. Our theoretical basis is built
upon concepts from the theory of the commons, power theorizing,
and notions related to data and information. Empirically, we investi-
gate openness in the genetics domain through a longitudinal study
of the evolving communal infrastructure for data related to 2 genes
influencing women's susceptibility to breast and ovarian cancer
(BRCA1 and BRCA2). We follow the continuously shifting “topology”
of the BRCA information infrastructure and trace the multiple
repositories that are put in place and the different arrangements
for data collection, curation/quality assurance, access, and control
that are tried out. In our analysis, we illustrate the actors' strategies
for curbing the subtractability and exclusion attributes of data. We
then propose a theoretically informed and empirically grounded
framework that can guide understanding and action taking to enable
data openness.
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The advent of genetic testing for clinical purposes and the rapid development of sequencing technologies led to an
exponential growth of genetic data. These data are valuable resources for both researchers and clinicians. Researchers- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 VASSILAKOPOULOU ET AL.draw on them to explore the relationship between genes and health outcomes and clinicians refer to them to support
clinical decisions related to diagnostics, treatment planning, and prevention (Battista, Blancquaert, Laberge, Van
Schendel, & Leduc, 2012; Bennett, Burke, Burton, & Farndon, 2010; Haga et al., 2012; Skirton, Patch, & Williams,
2005; Snyderman, 2012). Nevertheless, tensions abide in the genetic data governance area and different approaches
are being followed for data collection, curation/quality assurance, access and control. There are major initiatives
towards data sharing and openness, while there are also significant initiatives that adopt restrictive approaches for
pooling together and governing genetic data. The differences among actors' stances towards data openness and
enclosure are fueling controversies and contestations.
In this paper, we investigate data openness in the genetics domain through a longitudinal study of the evolving
infrastructure for data related to 2 genes that influence women's susceptibility to breast and ovarian cancer (BRCA1
and BRCA2). This is a significant domain as “a large proportion of the work in genetic services is the management of
familial breast and ovarian cancer, and this clinical area exemplifies both the opportunities and challenges to increasing
access to gene testing” (Slade, Riddell, Turnbull, Hanson, & Rahman, 2015). Our analysis spans the 2 decades elapsed
since the identification of the 2 specific genes. We adopt a utility perspective, emphasizing the use value of data and
conceptualizing them as “goods.” To gain insights, we use the Ostroms' typology of goods (Ostrom & Ostrom, 1977)
unpacking the notion of openness.
Our investigative concerns are 3‐fold: (1) to bring insights about openness in the specific BRCA data domain, (2)
to develop a critique for the prevailing practice of blackboxing openness, and (3) to suggest workable arrangements
for facilitating the equitable use of data resources in the field. These investigative concerns position our work within
critical information research (Myers & Klein, 2011). Critical information systems research is characterized more by the
type of investigative concerns and critical intentions rather than commonality in underlying theories (Brooke, 2002;
Cecez‐Kecmanovic, Klein, & Brooke, 2008; Stahl, 2008).
Our analysis provides insights about the impediments and opportunities for global data sharing and openness in
the much contested BRCA domain. Adopting a utility perspective and conceptualizing data as “goods,” we unpack
data openness along 2 key goods' attributes: exclusion and subtractability (Ostrom & Ostrom, 1977). Understanding
data openness entails examining the processes through which data are generated and used and the processes that
make them valuable. We explore these processes in the BRCA data domain by following the evolution of communal
BRCA data repositories, and we trace how the subtractability and exclusion attributes of data are continuously nego-
tiated and reshaped. The dynamics of subtractability and exclusion set data apart from biophysical goods where these
attributes are exogenous (ie, not shaped within the arena of action). In the contested domain of BRCA data reposito-
ries multiple actors leverage different forms of power to pursue or restrict openness by shaping subtractability and
exclusion.
The remainder of the paper is structured as follows. First, we present our analytical lens that entails conceptual-
izing data openness from a utility perspective. Subsequently, we present our research approach including motivation,
research context, and methods for data collection and analysis. Then, we present our empirical findings and analysis.
Finally, we discuss our findings in light of our overall aims and conclude by presenting implications of our work.2 | DATA OPENNESS FROM A UTILITY PERSPECTIVE
2.1 | Data as goods
A utility perspective orients attention to the use value of data. This value relates to the information that data can con-
vey to knowledgeable users (Kettinger & Li, 2010). From a utility perspective, data acquire value when used as infor-
mation resources. The use value of data is contextual and can be identified by tracing the role of data for performing
knowledge work tasks and the impact of data on task outputs (Repo, 1986). Hence, this value is dependent upon the
arrangements that make possible the realization of their potential (Aaltonen & Tempini, 2014).
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1999), and during utilization, data convey information to users that have prior knowledge (Kettinger & Li, 2010) and a
specific interest (an object) (Zimmerman, 2008). As different users use different knowledge configurations to make
sense of data (possibly also having different interests) the same data can result to different information (ie, different
object representations) (McKinney & Yoos, 2010).
Three decades ago, Cleveland explored the unique characteristics of information as a resource and noted that it
differs from traditional resources in that it is expandable (can increase with use rather than being consumed), com-
pressible, substitutable (in the sense that it can “replace” capital, labor, and physical materials when smartly used), dif-
fusive (it tends to leak), and sharable without being depleted (Cleveland, 1982, 1985). These characteristics of
information resources and especially the fact that information is leaky made Cleveland to proclaim that the winds
of openness are whistling, signalling the obsolescence of ownership for ideas or facts. Nevertheless, the generic char-
acteristics of information resources are not enough for mandating openness.
Although information is leaky, the rate by which it leaks can be painstakingly slow. In cases where information
timeliness and currency is of importance, it is possible to restrict the flow of benefits from information resources
by delaying their diffusion. Outdated information resources can bring little or no benefits under time‐sensitive condi-
tions. Furthermore, although information resources can be shared without being consumed, in many cases, sharing
can diminish the benefits accrued from them. For instance, when information resources are used to reduce capital,
labor, or material providing a competitive advantage, there are good reasons for safeguarding them.
To sum‐up, approaching data from a utility perspective (conceptualizing them as goods) entails linking data to
their use context, thus revealing the diversity of situations that influence their governance. Such a perspective goes
beyond the generic characteristics that relate to the nature of information resources (ie, that they are expandable,
compressible, substitutable, diffusive, sharable) and brings to the forefront both the characteristics of users (that have
specific prior knowledge and interests) and the characteristics of overall arrangements within which information will
play a resource role. The specifics of these arrangements are important for exploring the issue of openness.2.2 | The question of openness: insights from the typology of goods
The question of openness does not arise unless there is the possibility and desirability for non‐openness (ie, enclo-
sure). In the late 1970s Ostrom and Ostrom introduced a typology of goods aiming to disambiguate between regimes
for openness/enclosure and the nature of goods. For some time, economists had struggled with classifying goods as
either private or public. In their typology, the Ostroms clearly identified that there are more than 2 types of goods
(Ostrom & Ostrom, 1977). They used 2 attributes from the political economy literature that help identify 4 broad clas-
ses (Table 1). The first attribute is about the subtractability of goods' benefits. Subtractability signifies up to what
extent the benefits consumed by someone may subtract from the benefits available to others. For instance, in the case
of mineral goods like coal and petroleum, the benefits consumed by someone that uses a quantity mined are
subtracted from what is available for others. For non‐material goods, such as data or information, examples of
subtractability include the benefit of scientific publication, where results based on specific data are only novel once.
The second attribute relates to how difficult it is to exclude individuals from access to the flow of benefits (Hess &
Ostrom, 2003). Mechanisms for exclusion range from regulation of access rights to physical enclosure of the goods
or their distribution channels. For instance, exclusion is much easier for arable land than for ocean fisheries.TABLE 1 Typology of goods based on exclusion potential and subtractability
Subtractability
Low High
Exclusion Easy Club goods Private goods
Difficult or infeasible Public goods Common‐pool resources
Adapted from Ostrom and Ostrom (1977) and Hess and Ostrom (2003).
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The category of goods for which it is difficult or infeasible to implement exclusion measures for the flow of benefits is
characterized as “commons.” The “commons” can be governed as public goods or as common‐pool resources. The
classification of goods in 1 of the 4 broad classes does not automatically lead to an optimal governance regime but
it contours the action arena. For example, common‐pool resources can be linked to a variety of regimes: “common‐
pool resources may be owned by national, regional, or local governments, by communal groups, by private individuals
or corporations, or used as open‐access resources by whomever can gain access. Each regime has different sets of
advantages and disadvantages” (Hess & Ostrom, 2003).
What we found intriguing in the conceptualization proposed by the Ostroms is that the exclusion and
subtractability of goods are considered to be “external variables” (ie, exogenous factors not to be shaped within the
arena of action). While this might hold for biophysical goods (like ocean fisheries, arable land, forests, and sunshine),
it is not always the case with non‐material, handmade goods. For this type of goods, the exclusion and subtractability
attributes are not necessarily to be taken as given, on the contrary, these characteristics can be fabricated and are
technologically contingent. This opens up for an action arena where different actors influence the goods' attributes
by exercising different types of power.2.3 | The role of power within openness‐shaping action arenas
Clegg has theorized power within organization fields and proposed 3 circuits through which we can make sense of it:
(1) the episodic circuit that is associated to causal power in day to day relations; (2) the dispositional or social integra-
tion circuit that is linked to member relations, alliances, and authority legitimization; and (3) the facilitative or system
integration circuit that is related to change and the empowerment or disempowerment of agents (Clegg, 1989). What
is interesting in this model is that it includes both power exercised episodically (eg, during specific conflict instantia-
tions) and power that shapes the overall action arena (dispositional and facilitative). Furthermore, the model points to
the “juncture at which social and system integration meet (…) the stabilization and fixing of rules of meaning and mem-
bership, and techniques of production and discipline in an organization field” (Clegg, 1989: 241). Power is not only
manifested when conflict is present between the actors that have different stances towards data openness and enclo-
sure. The dispositional (social integration) and facilitative (system integration) circuits are 2 additional types of power
exercising that are especially important as actors are actively shaping, rather than simply addressing the exclusion and
subtractability properties of data.3 | RESEARCH MOTIVATION, CONTEXT, AND METHOD
3.1 | Motivation
The impetus for our study comes from our involvement in a research and development project within genetics. This
was a collaborative project between the Department of Medical Genetics in a large Scandinavian University Hospital
and the University in the same city. The aim of the project was to develop a secure IT platform to facilitate distributed
collaboration and access to a high‐performance analysis and storage facility. As one of the research activities in that
project, we conducted interviews and observations of how molecular biologists and other specialists conduct their
work. During our observations we were struck with the role of external databases and tools. We started further inves-
tigations into the international “ecology” of data resources via secondary data collection (documents, reports, research
papers, etc). Our investigation was focused on BRCA variant assessment datasets, starting with the Breast Information
Core, a globally shared database that was established in 1995. We downloaded the content of the database, analyzed
the patterns of submissions, and examined the content of the records. This analysis brought to light a surprising find-
ing: although BIC is a highly valuable database for the clinical genetics specialists, the richness of its content decreased
FIGURE 1 Breakdown of Breast Cancer Information Core entries by creation year for the 1997‐2009 period (analysis
of database instance downloaded on September 17, 2014)
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contributor to BIC up to that point) to stop sharing data.
This surprising finding triggered our interest to explore issues of openness and enclosure in the domain and led us
to investigate the diverse value logics that are present (Vassilakopoulou, Skorve, & Aanestad, 2016a) and to address
genetic data governance through a commons perspective (Vassilakopoulou, Skorve, & Aanestad, 2016b). Although our
research interest when entering the project was of a technical nature (revolving around software and network solu-
tions that could facilitate practitioners' everyday work), the analysis of the content of the datasets triggered an inter-
est to get better insights on the tensions around data openness within the domain. We realized that to facilitate the
unobstructed and equitable use of valuable data resources in the domain, it was not sufficient to propose technical
solutions (for user‐friendly interface design and for efficient linkages among heterogeneous data containers). It was
also important to take a critical perspective and aim for insights to address longstanding patterns of exclusion.
Pursuing this research interest, we studied the evolution of BIC starting from its inception and following its tra-
jectory looking at key decision points and conflicts over the years. Starting from BIC we expanded our coverage to
other related initiatives and collated data to produce an account of the information landscape evolution with the
aim of examining how openness is achieved or obstructed. On the basis of a critical approach, we understand the
domain of data sharing as a contested domain and data as valuable goods around which contests may arise.3.2 | Research context: BRCA testing
In 1990, the geneticist Mary‐Claire King and her team discovered the linkage between a gene on chromosome 17 and
breast cancer predisposition (Hall et al., 1990). The discovery of this linkage triggered an intense race among research
teams around the world to sequence the gene and to develop relevant genetic testing procedures that led to the iden-
tification of BRCA1 in 1994 and of BRCA2 in 1995. Having a pathogenic BRCA1 or BRCA2 variant can increase a
woman's risk of developing breast cancer to between 50% and 80% (the general population risk is 12%) and the risk
of developing ovarian cancer to between 24% and 40% (the general population risk is 1%‐2%) (Petrucelli, Daly, &
Feldman, 2013). This means that a BRCA test can be used not only for diagnostic purposes but also as a pre‐symptom-
atic test to check for disease predisposition. The identification of the BRCA genes made genetic testing possible not
only for diseases that are inherited from generation to generation (like thalassemia or cystic fibrosis) but also for dis-
eases were genes are one of many causative factors (eg, both inheritance and environment play a role).
Although a predisposition does not mean that the disease will certainly appear (significant numbers of women
that carry pathogenic BRCAmutations have reached their 90s without developing breast or ovarian cancer), a positive
test can trigger medical interventions that can be as radical as mastectomy or ovary removal. Genetic testing in the 2
BRCA genes is aimed towards identifying the presence or absence of cancer predisposing gene variants (mutations).
Testing entails mapping the gene sequence for a specific individual and comparing it with what is most commonly
encountered in the general population. Differentiations (variants) from the common sequence are assessed by experts
and classified as follows: variants that indicate pathogenicity, variants that do not indicate pathogenicity, or variants of
uncertain/unclassified clinical significance. The assessment of variants' pathogenicity is based on experts'
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this reason, data repositories play a critical role (Aronson & Rehm, 2015).
The process of BRCA genetic testing includes sampling (eg, taking a blood sample), sample processing with the
use of a specialized machine (sequencer), variant identification using informatics tools, and variant assessment. Each
part of the process is significant. Nevertheless, performing the first stages of the process that lead to variant identi-
fication is relatively straightforward and largely automated. The major challenges remain for variant assessment
(Quintáns, Ordóñez‐Ugalde, Cacheiro, Carracedo, & Sobrido, 2014). BRCA1 and BRCA2 are genes that produce
tumour suppressor proteins. These proteins help repair damaged DNA. When either of these genes is altered in
way that its protein product is not made or does not function correctly, DNA damage may not be repaired properly.
As a result, cells are more likely to develop additional genetic alterations that can lead to cancer (National Cancer Insti-
tute at the National Institute of Health—USA, 2014). Since not all variants have the same impact on gene function, the
identification of a variant (ie, a differentiation from what is most commonly encountered in the general population) is
not enough to signify cancer predisposition. The impact of the variant has to be assessed before reaching a
conclusion.
To perform the assessment, experts search for prior variant classifications in datasets containing anonymized
results from past BRCA genetic tests. Search can be performed in local data repositories (containing results from past
tests performed by the same laboratory) or in shared ones (where many laboratory test results deposit test results) or
in published scientific papers and reports. Additionally to looking up prior classifications, scientists can perform differ-
ent types of analysis for the variant identified. Such analysis may entail specialized predictive models and software
packages. It may also entail experimentation and measurements performed on organic material (as opposed to com-
puter simulations), in a controlled environment to define protein functionality. Furthermore, family studies
(performing tests to relatives) may also be initiated. The availability of good quality datasets on past assessments
can significantly facilitate the assessment of variants minimizing the need for further analysis and reducing the dupli-
cation of efforts within laboratories around the world. In this context, the role of databases is critical. The laboratories
that have access to reliable data on past assessments can expedite their work, while laboratories that have no such
access (and the population that gets tested in these laboratories) are disadvantaged. In that sense, the issue of open-
ness and enclosure in the domain is of significant societal relevance.3.3 | Method for data collection and analysis
In the previous sections we presented the research context and the dynamics of our research process. We provided
an account of our research motives explaining how they were guided by the unfolding pattern of findings (McGrath,
2005). Our concern for investigating openness in the BRCA domain oriented our attention to the interests that are
driving enclosure and the arrangements in place that dictate the inclusion or exclusion from the flow of data benefits.
For our investigation we followed a process approach paying attention on how and why things emerge, develop, grow,
or terminate over time (Langley, Smallman, Tsoukas, & Van de Ven, 2013). Our methodological approach has similar-
ities to genealogical approaches adopted by Foucault; historical investigations into the events that have led to the cur-
rent status. Foucault eschews grand narratives and emphasizes the importance of the local relations and actions
(Klecun, 2004), and this paradigm can guide research that aspires to focus on the negotiated nature of established
arrangements. To build our empirical basis, we aimed to (re)construct the BRCA data repositories' trajectory that
spans more than 2 decades by collecting documentary evidence, performing semistructured interviews and inspecting
digital artefacts (actual BRCA repositories). This effort yielded a significant volume of data (Table 2).
We analyzed the data collected by focusing on the evolution of events related to BRCA data governance. To gain
insights, we used the Ostroms' typology of goods (Ostrom & Ostrom, 1977) for unpacking the notion of openness in
the domain. Initally, the collected data were analyzed by reconstructing a chronology of events. Then, we analyzed our
empirical material by putting together episodes that relate to subtractability and exclusion. As we proceeded with the
analysis, we identified gaps in our empirical material and we extended the data collection. We also engaged in
TABLE 2 Data sources
Source Description Topics Covered
Interviews 12 semistructured interviews
with scientists engaged in
medical genetics (biologists,
bioinformaticians, medical
doctors).
Repositories used and work practices,
data exchanges with other scientists
insights on ongoing developments in
the field related to data sharing.
These interviews helped us to orient
within the field and to make sense of
data utility.
Data
repositories
inspection
Inspected the BIC, ClinVar
and BRCA exchange repositories
For BIC: analyzed the patterns of submissions
and examined the content of the records.
For ClinVar: retrieved BRCA variant data and
examined the information consolidation
mechanisms used.
For BRCA Exchange: retrieved BRCA variant
data and explored the different views
provided (including a curated list of BRCA
variants, interpreted by expert consensus).
Document analysis Journal papers, media publications,
scientific guidelines, nomenclature
documents, legal proceedings,
project reports, presentations
prepared for various audiences
Reviewed 330 documents to identify key events
that mark the evolution of the overall
information infrastructure and to gather
information on public debates for
controversial issues.
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vant additional sources or point out relevant episodes. Our analysis brings insights about the exclusion and
subtractability attributes of gene‐specific datasets of genetic variant assessments. For such valuable sociotechnical
goods, the attributes that shape openness are contingent to the overall arrangements they relate. These arrangements
are in flux as technology is being leveraged simultaneously by several actors to enable favourable conditions for open-
ness and by several other actors to create favourable conditions for enclosure.4 | A BRIEF GENEALOGY OF COMMUNAL REPOSITORIES FOR BRCA
VARIANTS
In the sections that follow we present a brief genealogy of communal repositories for data on BRCA variants. Our nar-
rative includes a part dedicated to open communal repositories and a part on non‐open hybrid communal repositories
with restrictions. The narrative is complemented by a table that provides an overview of both types of communal
BRCA data repositories (Table 3). In the figure that follows (Figure 2) we provide a timeline of key milestones for
the different initiatives described. The milestones are colour‐coded; white boxes illustrate initiatives towards open
data sharing while grey boxes illustrate initiatives that adopt restrictive approaches.4.1 | The advent of open communal repositories
The need for putting in place communal variant repositories was identified early after the BRCA discoveries. In 1995,
10 scientists from universities, hospitals, a research institute, and a private company in different European countries
and the United States created an open Web‐accessible repository for BRCA data named Breast Cancer Information
Core (BIC) (Friend et al., 1995). BIC's aim is explained in a 1996 paper: “One of the serious impediments to achieving
clinical benefits from the isolation of the BRCA1 gene is finding and assessing the significance of mutations in this new
cancer susceptibility gene. This will be greatly facilitated by coordinated detection and interpretation of mutations and
TABLE 3 Communal BRCA data repositories as of April 2017
Repository
Name
When
Started
Deposit
Policy Access Policy
BRCA
Variants Description
BIC 1995 Open discretionary
curated
Open after
registration
4 000 A Web‐accessible repository that
facilitates the accumulation and
sharing of BRCA variant
assessments. Data are accessible
by all. New data included after
being reviewed by volunteering
experts.
HGMD 1996 Curated
pulled
from
literature
Updated data
by
subscription.
3‐year old
data open
after
registration.
3 900 A repository for gene variants
and their interpretation
accessible via subscription.
A free version is also provided
but contains data appearing
with a time delay. The variants
listed in are manually curated
from the scientific literature.
LOVD
shared
2005 Open discretionary
curated (some
“pull”
mechanisms in
place)
Open 3 900 A free, open software for the creation
of locus‐specific databases
developed by the Leiden University.
Database administrators who have
set up their own installation can
activate the “share option.” Publicly
available Web interface.
SCRP 2012 Open discretionary Open
(via ClinVar)
2 000 A mechanism for collecting BRCA
variant assessments via doctors that
receive test results from Myriad in
the United States.
ClinVar 2012 Open discretionary Open 12 400 An aggregator of variant interpretations
(in an open, Web‐accessible
repository). The repository covers all
genes (not only BRCA variants). Data
deposited by multiple contributors—
not curated.
BRCA
Exchange
2015 Pulled from
multiple sources,
curated
Open 16 900 A Web portal to share expert‐reviewed
BRCA variant classifications. A new
pull model is implemented for the
proactive identification and
aggregation of data.
BRCA
Mutation
Database
2015 Curated pulled from
literature
Open 2 600 An open repository realized after a
University of Utah initiative. Entries
are created “in‐house” through
extensive literature curation and the
application of computational
methods.
BRCA
Share
2015 (based
on UMD
established
in 2000)
Participants only
(full sharing
required),
curated
Participants
only
6 200 A public‐private data sharing initiative.
Participation is possible for all
laboratory test results on a fee basis
(free for research) as long as they share
all their data.
8 VASSILAKOPOULOU ET AL.the dissemination of this information to as many qualified investigators as possible. To this end, the BIC has created
and maintains a central repository for information regarding mutations and polymorphism” (Couch & Weber, 1996).
BIC has accumulated up to today more than 30 000 anonymized entries corresponding to approximately 4000
distinct BRCA1 and BRCA2 variants. Data are deposited by individual investigators, research, hospital‐based, and com-
mercial laboratory test results, and are published after being examined by BIC's steering committee members. Regis-
tration is open to all, and access to registered users is unrestricted. Hundreds of submitters around the world support
FIGURE 2 Timeline of communal BRCA repositories (white boxes illustrate initiatives for open data sharing, and grey
boxes illustrate initiatives for restrictive approaches)
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into account the growth in BRCA testing, it becomes evident that the repository receives only a small portion of
the globally generated information. For instance, it has been reported that more than 100 000 BRCA tests are
performed annually in the United States alone (Armstrong et al., 2015).
Myriad is the most publicized non‐contributor to BIC. This is the world's largest molecular diagnostic clinical lab-
oratory (Myriad Genetics, 2014), which dominates the BRCA genetic testing market in the United States. Myriad was
founded in 1991 as a spin‐off from the University of Utah's Centre for Genetic Epidemiology to support the geneticist
Mark Skolnick and his team in the sequencing of BRCA1, and in the subsequent development of a test. Skolnick's team
won the BRCA1 race against many other research groups and filed patent applications on BRCA1, and soon after on
BRCA2. Myriad's dominant position in genetic testing can be attributed to the 9 BRCA1 and BRCA2 related patents,
which the company was granted with between 1997 and 2000. Myriad was the most significant contributor to BIC
until 2004 when a decision to stop contributing was taken. The company explained this decision by claiming that
BIC lacks operational and clinical standards and includes data of questionable quality as a high proportion of variants
is classified as of “unknown clinical importance” (Angrist & Cook‐Deegan, 2014; Tucker, 2014). In 2013, the US
Supreme Court invalidated Myriad's patents but the company retained a competitive advantage by having
accumulated a unique dataset in a proprietary database (Baldwin & Cook‐Deegan, 2013). The database is being used
internally for looking‐up variants traced in the past and has also been leveraged for the development of a scoring
algorithm for variant assessment (Pruss et al., 2014).
As a reaction to Myriad's decision to discontinue BIC contributions, 2 geneticists initiated a project named “Sharing
Clinical Reports Project” (SCRP) reaching out for physicians that receive Myriad's test reports (Nguyen & Terry, 2013).
SCRP was initiated in 2012 (Kolata, 2013) and received since then more than 5000 submissions related to more than
2000 unique BRCA variants (Sharing Clinical Reports Project, 2014). Soon after the initiation of SCRP a complementary
project entitled “Free the Data”was launched. This project addresses patients providing them a platform for sharing their
own BRCA reports and giving them the option to contribute additional health‐related information (Free the Data, 2014).
In 2012, the US National Center for Biotechnology Information released a new open repository (named ClinVar)
to host anonymized data on variant interpretations (Landrum et al., 2013) and invited scientific groups that hold data
from clinical testing, research, and literature to contribute their information. ClinVar is repository that covers all
human gene variations and is not dedicated only to the BRCA genes. A number of hospitals and laboratory test results
that were not submitting actively to BIC started submitting data to ClinVar. Additionally, both BIC and SCRP are reg-
istered ClinVar submitters and have contributed interpretations for all their variants. Submitted interpretations for a
particular variant are presented through comprehensive views that associate multiple submissions. Conflict resolu-
tions can be provided from expert panels or professional societies (Landrum et al., 2013). Unlike BIC where the con-
tent of submissions is reviewed by members of its steering committee and each variant interpretation is periodically
10 VASSILAKOPOULOU ET AL.updated to reflect the latest findings, in ClinVar the original content of the submissions is not curated or modified. As
of April 2017, ClinVar hosted information on 12 400 BRCA1 and BRCA2 variants (among them 842 with conflicting
interpretations). One of the positive aspects of ClinVar, according to the medical director of the molecular genetics
and genomics department of a large laboratory, is that it alerts laboratory test results when the classification for a var-
iant differs between them: “We can get on the phone and talk with the other laboratory. We may simply have differ-
ent internal evidences that we are using” (Ray, 2015). By sharing information laboratory test results can advance their
understanding on BRCA variants and improve their interpretations.
Both BIC and ClinVar rely on discretionary submissions of multiple laboratories that “push” information in the
shared repository. Following a different, “pull” approach, in June 2015 a new Web portal named BRCA Exchange
was launched under the auspices of the Global Alliance for Genomics and Health. The Global Alliance is an impressive
network of major health care providers, research funders, research institutions, disease advocacy organizations, and
life science and information technology companies. The network's aim is to create a common framework of harmo-
nized approaches to enable the responsible, voluntary, and secure sharing of genomic and clinical data (Global Alliance
for Genomics and Health, 2015). BRCA Exchange aims to facilitate open sharing of expert‐reviewed BRCA variant
classifications. A number of working groups with members located around the world are working within this initiative
to identify sources of classified variants to be aggregated and also, unclassified variants with evidence, which can then
be interpreted, classified, and aggregated. Essentially, BRCA Exchange does not rely to the depositors' initiative for
data collection but rather, proactively exploits existing data sources through standardized application programming
interfaces (APIs) and procedural conventions. ClinVar is used as a major source of information. The classified variants
are displayed at the BRCA Exchange portal for “use by clinicians, patients, and labs to enable accurate understanding
of any individual BRCA1/2 variant, for superior clinical care and decision‐making” (BRCA Exchange, 2015). As of April
2017, BRCA Exchange included more than 16 900 unique BRCA variants.
Following another approach for pulling together existing information and making it easily available to all, the
University of Utah's Department of Pathology together with its nonprofit ARUP Laboratories launched in May
2015 the open BRCA Mutation Database (Ray, 2015) in collaboration with the University's Huntsman Cancer
Institute and with the WHO International Agency for Research on Cancer. This new open communal repository
for information on BRCA1 and BRCA2 variants provides 2 types of datasets: (1) classified variants found in the
literature and family studies (containing information on more than 2600 variants) and (2) in silico risk predictions
for all possible single nucleotide substitutions in BRCA1 and BRCA2 to support variant interpretation. Practically,
the BRCA Mutation Database is not populated by information deposited by third parties or pulled from pre‐existing
databases but the entries are created “in‐house” through extensive literature curation and the application of
computational methods.4.2 | The advent of hybrid communal repositories with restrictions
During the 1990s a team within the French Institute of Health and Medical Research (INSERM) initiated the develop-
ment of a generic software called UMD (Universal Mutation Database) for the creation of locus‐specific databases.
Locus‐specific databases are collections of variants limited to a specific gene (eg, the BRCA genes), as opposed to
more general databases. The first version of UMD was released in 2000, and since then it has been continuously
upgraded and improved (Béroud et al., 2005; Béroud, Collod‐Béroud, Boileau, Soussi, & Junien, 2000; Caputo et al.,
2012). UMD was used to develop BRCA1 and BRCA2 databases that include curated, compiled information from 16
laboratories located all over France belonging to the GGC consortium (Groupe Génétique et Cancer). These databases
have been endorsed by the French National Cancer Institute (INCa) and were designed to collect all BRCA variants
detected in France.
In April 2015, INSERM in collaboration with the commercial laboratory Quest Diagnostics announced the launch
of BRCA Share, which is a novel BRCA repository that builds upon the existing BRCA data in the UMD BRCA data-
bases (the repository contains data on more than 6200 BRCA variants). BRCA Share is a public‐private initiative, with
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tories have to commit on sharing past, present, and future data. Commercial laboratory test results need to pay a sub-
scription fee according to their size, while research entities get access at no cost. This financial arrangement allows
BRCA Share to invest on data curation arrangements to attend to data quality and to conduct functional studies on
the effects of mutations, without depending on research or public funding. Curation refers to the quality assurance
process of data and often includes manual evaluations by multiple specialists. This is a crucial issue that requires
extensive resources, especially when the depositors and their local procedures prior to submission are not well known.
Essentially, BRCA Share's alternative model resembles a “club arrangement” and was described by a Nature editorial
as a “walled garden” (Nature Editorial, 2015).
A similar logic to the one introduced by UMD has been followed for the Leiden Open Variation Database (LOVD),
which is a dedicated software for the creation of locus‐specific databases developed by the Leiden University Medical
Center in the Netherlands. LOVD is a free, open‐source tool that was launched in 2005 and is actively being improved,
currently having new releases every month (Fokkema et al., 2011; Fokkema, den Dunnen, & Taschner, 2005). Data-
base administrators who have set up their own installation can activate the “share option” for anonymized data.
TheWeb interface is publicly available and can be freely searched, but other activities, including sequence variant sub-
mission, require prior registration. The LOVD shared installation (which is accessible by anybody) includes more than
3900 unique public BRCA variants.
Back in 1996, a repository named Human Gene Mutation Database (HGMD) was made publicly available (Cooper
& Krawczak, 1996; Krawczak et al., 2000). The repository was maintained at the Institute of Medical Genetics in
Cardiff in the United Kingdom and contained data on gene mutations underlying human inherited disease. HGMD
was built upon a database that 2 geneticists developed in the early 1990s to collate data for the study of mutation
mechanisms in human genes (Krawczak et al., 2000; Krawczak & Cooper, 1995). In 2000, HGMD entered a licensing
agreement with the company Celera Genomics and agreed to provide Celera exclusive access to new information
added for a 1‐year period (Stenson et al., 2003). The updated HGMD content was thereafter available on a paid
subscription basis, while a free version was also provided via the Cardiff website (containing data appearing with a
time delay). This agreement lasted until 2005. Since 2005, HGMD has been working in partnership with another
company (BIOBASE GmbH) using a similar business model (Stenson et al., 2012). The publicly available version of
HGMD is still maintained and is accessible free of charge but is out‐of‐date by 3 years. Since 2006, access to the
publicly available version is provided after registration and is only granted to users from academic/nonprofit
institutions (Stenson et al., 2009). The variants listed in HGMD are sourced and manually curated from the scientific
literature. Relevant literature is identified via a combination of manual journal screening and automated procedures
covering more than 1950 journals (Stenson et al., 2014). HGMD does not include only data related to BRCA1 and
BRCA2 but its BRCA related content is rich: the free version of HGMD contains more than 3000 BRCA variants
(the subscription version contains about 30% more).4.3 | Current state: a fragmented landscape
The initiatives presented in the previous sections are summarized in Table 3 revealing the fragmentation and hetero-
geneity of the evolving BRCA information infrastructure.
The multiplicity of repositories does not only result to duplication of efforts and increased difficulty in data
retrieval. More significantly, as different repositories follow different approaches for data collection and curation they
end up conveying inconsistent information. In a comparative study (initiated by Myriad), the data content across 5
different BRCA data repositories (BIC, ClinVar, HGMD Pro, LOVD, and UMD) were analyzed (Vail et al., 2015). The
researchers investigated how many of a set of 1327 variants from Myriad's database were included in the communal
repositories (only 124 were found in all 5) and compared the classifications for internal and cross‐repository consistency.
The finding of this investigation was that different sources often provide different assessments for the same variant.
12 VASSILAKOPOULOU ET AL.5 | ANALYSIS
5.1 | Data flows within the domain
The continuous efforts of multiple distributed actors make possible the flow of BRCA data globally. Patient samples
are processed in genetic laboratories where the variants identified are assessed and filed in local repositories. The
assessment work is supported by data on past variant assessments retrieved from communal repositories. Some of
the newly generated data are shared (submitted for publication to journals or deposited for inclusion in repositories).
Data curators and repository managers are facilitating and controlling data gathering (overview in Figure 3).
The sharing of variant assessments is pivotal for distributing the labor required for characterizing variants and
avoiding the duplication of efforts, for identifying and resolving differences in interpretation, and for providing a cat-
alogue of variation that could be used for research. However, the accumulated data in the communal repositories are
only a small part of the data generated in the various laboratories. Large volumes of data are stored locally and remain
inaccessible as significant effort is required for putting data in a shareable format and linking them or uploading them
to communal repositories. In some cases, laboratories may also have an incentive for keeping their data for proprietary
use, especially in the cases when they have to operate within a market environment. Even data that become part of
the public domain (eg, through scientific publications) require significant effort and costs for becoming easily retriev-
able. Furthermore, some of the repositories that pool together this type of data are only available on a subscription
basis. Although several scientists have been vocal about the need to ensure sharing in the domain (Cook‐Deegan,
Conley, Evans, & Vorhaus, 2013; Field et al., 2009; Matloff, Barnett, & Nussbaum, 2014; Nature Editorial, 2015;
Tucker, 2014) and large‐scale investments supported by governments and international organizations are made, uni-
versal data sharing remains a vision. This situation is linked to the exclusion and subtractability attributes of BRCA
datasets that do not foster a universal approach to openness. In the following sections we explore the shaping of
those 2 key attributes.FIGURE 3 Data flows within the BRCA information infrastructure
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In the case of private laboratories that compete within market conditions data sharing can be undesirable. Actually,
the benefits that other laboratories might appropriate by reusing the data shared can subtract to an extent from
the advantage of the laboratory that completed the assessment in the first place. Through data sharing, laboratories
that have already incurred assessment costs enable competitors to benefit without exerting the same efforts, losing
some competitive advantage when the same variant is encountered. Actually, 2 of the unique characteristics of infor-
mation as a resource, substitutability and expandability (Cleveland, 1982, 1985), are creating the conditions for high
subtractability. Information on past variant assessments can substitute some of the analysis labor required creating
a competitive advantage for those that possess such information. Moreover, information on variants is expandable;
it can be further manipulated with advanced models to produce new insights that commercial laboratories may exploit
as trade secrets.
To counteract the tendency of laboratories to keep valuable information for their own use, practice guidelines
mandate public disclosure when “a variant of uncertain clinical significance becomes clearly pathogenic, or a variant
is not pathogenic anymore” (Wallis et al., 2013). Furthermore, proponents of openness are negotiating with the
College of American Pathologists (a leading accreditation organization for diagnostic laboratories) to make data
sharing a condition of membership, while some of the insurance companies consider making it a requirement for
reimbursement (Krol, 2014).5.3 | Exclusion
As BRCA data are generated in multiple laboratories around the world, they are first registered in multiple dispersed
sites. The variant assessments are communicated to health care providers and patients; therefore, practically it is not
possible to prevent individuals from disseminating them as the SCRP initiative proves. Furthermore, exclusion is con-
sidered incongruent with the scientific tradition of medical genetics, where data sharing is valued not only for the
potentiality of advancing scientific knowledge but also for the preservation of information and for safeguarding
against misconduct (van Schaik, Kovalevskaya, Protopapas, Wahid, & Nielsen, 2014). Still, exclusion phenomena
prevail.
Information as a resource is diffusive and sharable (Cleveland, 1982, 1985). Technology offers the possibility for
information to be easily digitized and shared, and it can start flowing towards public databases but this kind of flow
can be painstakingly slow. Standardization and networking have been used by different actors in the BRCA field for
making sharing a seamless activity and accelerating data flows. For instance, in the case of laboratories that use inter-
nally the same software (eg, LOVD or UMD) there is the possibility of real‐time data sharing. Pull mechanisms to
proactively amass data have also been created (as in the case of BRCA Exchange) to ensure more timely and
comprehensive data sharing. Furthermore, specialized tools to facilitate data evaluation during curation activities
are being used to significantly reduce the effort required for ensuring data quality. Overall, connectivity and
communality (Fulk, Flanagin, Kalman, Monge, & Ryan, 1996) are being used by several key actors to counteract
exclusion tendencies in the domain. Connectivity is pursued via technical solutions and standards, while communality
is pursued via curators, trusted third parties, or specialized committees.6 | DISCUSSION
In our analysis we explored how data openness can be unpacked by conceptualizing data as valuable goods and by
leveraging the typology of goods proposed by Ostrom and Ostrom (1977). This typology is built around 2 key attri-
butes: subtractability and exclusion. While contributions on data openness abound in the IS literature, including stud-
ies on open data in health care and public sector (eg, Alanazi & Chatfield, 2012; Kuk & Davies, 2011; Laine, Lee, &
Nieminen, 2015), it is striking that the meaning of data openness is black‐boxed. We suggest that unpacking openness
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one possible approach towards achieving this. As the analysis of the evolution of data repositories in the BRCA
domain shows, subtractability and exclusion are being shaped by actors that participate in the field with different posi-
tions and different interests. The genetics field is densely populated by public and private actors of varying sizes, dif-
ferent roles (eg, laboratories performing tests, information service providers, clinical units, research units), and
different business models. The exclusion and subtractability of data goods are not exogenous factors (as for biophys-
ical goods) but rather are being fabricated by the different actors within this arena of action. Subtractability and exclu-
sion are shaped by all these participants (that can be data depositors, data users, data curators) and also by actors that
finance health care (that set their own rules having an interest in improving efficiency), health policy makers (that take
measures aiming to the sustainability and the continuous improvement of health systems), and citizens (that influence
the political arena). Ensuring access to data is important for pursuing human well‐being, for complying with norms of
scientific evidence, and for advancing medicine, but is not yet built into the system (Cook‐Deegan & McGuire, 2017).
This has been emphasized by the National Research Council of the US National Academies that identified the need to
build “information commons” based on data sharing to advance precision medicine and improve health (National
Research Council, 2011).
Many groups have been working during the past 2 decades to address BRCA data sharing issues, pooling data on
BRCA genetic variants sourced from laboratories, research enterprises, clinicians, and published research through
diverse approaches and data governance schemes (Béroud et al., 2000; Cooper & Krawczak, 1996; Fokkema et al.,
2005; Friend et al., 1995; Landrum et al., 2013; Lawler et al., 2015). Despite the intense activity in the domain, the
various efforts have not converged into a dominant governance model and the vision of ensuring access to data
remains largely unfulfilled. Our analysis shows that developing workable arrangements for openness requires finding
ways to ensure that the benefits consumed by data users will not subtract from the benefits of actors that possessed
the data in the first place. Furthermore, it requires finding ways to prevent exclusion from access to the flow of ben-
efits. This points to the importance of power exercising through the dispositional and facilitative circuits. The dispo-
sitional (social integration) circuit provides the conditions for actors to exercise power. The importance of this
dispositional power for pursuing openness or enclosure (depending on actors' interests) is manifested in efforts to
promote data sharing in policy documents, and guidelines by openness proponents. At the same time, those that
oppose openness are developing arguments based on the (lack of) data quality in open repositories (Vail et al.,
2015). While dispositional power is concerned with the capacities to configure legitimization conditions, facilitative
power can be both disciplinary and generative as it relates to the creation of outcomes and change. It is defined by
the techniques of production and discipline within the domain. It relates to systems of rewards and punishment
and technologies, job design, and networks. Facilitative power is manifested in the BRCA case as new technologies
are leveraged within targeted initiatives that aim to disrupt the status in the domain (eg, SCRP and BRCA Exchange).
Clegg uses the term “techniques of production” for the technological means of controlling the physical and social envi-
ronment in organizations and refers to these techniques as an example of facilitative power that comes into play in the
system integration circuit (Clegg, 1989). The role of information and communication technologies for facilitating open-
ness in the domain is key. New governance arrangements will require thinking of actors' relations by taking into
account also technology design (Van den Hoven, 2007). The impressive growth of the BRCA Exchange dataset is
related to the decision to leverage technologies for automatically pulling data from multiple pre‐existing repositories.
Furthermore, the connectivity afforded by Web technologies is leveraged for enrolling multiple qualified scientists
from all over the world in massive curation and quality assurance activities. The BRCA Exchange initiative targeted
simultaneously data sourcing, quality assurance, and access.
Power and divergent interests are ever present in domains as complex as the genetics one. The traditional Webe-
rian definition of power (“the probability that one actor within a social relationship will be in a position to carry out his
own will despite resistance, regardless of the basis on which this probability rests” (Weber, 1947: 152)) is often
interpreted as precluding manifestations of power unless there is some sort of resistance (or conflict). Nevertheless,
power exercised through the dispositional and systemic circuits is key for establishing workable arrangements for
TABLE 4 Possible interventions to influence exclusion and subtractability
Possible Interventions to Shift Towards Openness
Dispositional Power Facilitative Power
Influence on
data (goods)
attributes
Exclusion For instance, building a case for
sharing in policy documents,
building relations and alliances.
For instance, through technologies
that facilitate data pulls and distributed
curation.
Subtractability For instance, working with social
norms for contributions within
collectives, building a case
against free‐riding.
For instance, through technologies to
trace and attribute contributions,
mechanisms for credit to parties
involved, rules for test provider selection.
VASSILAKOPOULOU ET AL. 15openness. In Table 4, we present possible ways to shift the domain towards openness by influencing the
subtractability and exclusion attributes of BRCA data. These ways entail leveraging dispositional and facilitative power
and are built upon the findings from the case analyzed. In a complex global domain as the one studied, there will
always be multiple actors working under different jurisdictions, with different interests and orientations. Hence,
although it is difficult for openness to be mandated, the conditions for openness can be cultivated in the domain
by those interested in advancing medical knowledge and human well‐being. Unpacking openness and making sense
of how different forms of power exercising can shape the action arena is a good start for such interventions.
Interventions like the ones presented inTable 4 can support the creation of a more favourable to openness envi-
ronment. This would not preclude individual actors from pursuing strategies of enclosure. As Cook‐Deegan and
McGuire have noted in a recent paper, the viability of the openness model depends in part on how good public data-
bases become; if communal data sources accessible to all “catch up” to proprietary ones, strategies based on enclosure
will lose much of their marginal value (Cook‐Deegan & McGuire, 2017). In this context, we especially want to draw
attention to the role of information systems as means for exercising facilitative power to shape the subtractability
and exclusion attributes in the BRCA data domain. There are already significant successes with technological arrange-
ments that facilitate data flows (addressing the exclusion characteristic of BRCA data). A next step could be to capi-
talize on technological possibilities for enhancing non‐subtractability. This can be aimed, for instance, through
technologies that trace and attribute contributions, and mechanisms for credit to parties involved. Technology can
also be used to strengthen strategies of enclosure either within private or club arrangements. Information systems
research can contribute in the shaping of the domain, revealing and explaining both the role of information and com-
munication technologies for producing socially desirable consequences and the risks of building technology‐enabled
enclosure arrangements.7 | CONCLUSION
Sharing valuable data at a global scale depends on the sustained work of many participants. In this paper we examined
the issue of openness by analyzing a specific case of genetic data (anonymized datasets on BRCA variant assess-
ments). Our analysis can provide a better understanding of the impediments to global sharing and the opportunities
for moving towards more open arrangements. Understanding data openness entails examining the processes through
which data are generated and used and the processes that make them valuable. We explored these processes in the
BRCA data domain by following the evolution of communal repositories showing how the subtractability and exclu-
sion attributes of BRCA data are not exogenously defined but are continuously negotiated and reshaped. Following
our investigative concerns we bring insights about openness in the specific domain and we contribute to unpacking
openness through conceptualizing BRCA data as goods that can be analyzed in terms of subtractability and exclusion
using the typology proposed by the Ostroms (Ostrom & Ostrom, 1977). Furthermore, we suggest ways to put in place
workable arrangements for promoting data openness in the field by pointing to the role of non‐causal power. Having
an action orientation is an implication of taking a critical stance: “the responsibility of a researcher in a social situation
16 VASSILAKOPOULOU ET AL.does not end with the development of sound explanations and understandings of it” (Ngwenyama & Lee, 1997: 151).
Specifically, we identify how dispositional and facilitative power (Clegg, 1989) can be leveraged to shift the domain
towards openness by curbing the subtractability and exclusion attributes of data. Hence, we contribute a theoretically
informed and empirically grounded framework that can guide both the assessment of the data sharing situation in the
field and action taking. Although the framework is illustrated by interventions (Table 4) that are specific to the
BRCA data domain and the multiple systems and practices within its information infrastructure (Figure 3), it can be
re‐contextualized for analyzing different data domains and identifying interventions.
Taking a utility perspective on data (conceptualizing them as goods) and thinking in terms of dispositional and
facilitative power can guide understanding and action taking. Within the current dynamic and multi‐actor data land-
scapes, it is possible to take openness‐oriented initiatives that are different from mandating openness (through causal
power). Dispositional and facilitative power can be exercised to curb exclusion and subtractability by targeted inter-
ventions in data sourcing (mobilizing and facilitating depositing), data quality assurance (stimulating and supporting
curation activities), data access (promoting and easing search and retrieval), and data crediting‐rewarding (fostering
and enabling tracing, attribution, and rewarding of contributions). Such initiatives can be part of concerted action
for data openness in domains where the societal significance of openness is justified. Relevant domains include scien-
tific research (OECD, 2004) and public government (Dawes, Vidiasova, & Parkhimovich, 2016). Information systems
research offers a unique knowledge base that can advance open data across domains (Link et al., 2017). Openness
can be a specific praxis‐oriented theme for critical information systems research aiming to more equitable data
arrangements (Richardson & Robinson, 2007).
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